Table 2. Summary of guidelines and consensus statements for CRC surveillance in IBD.
| Society | Year | Initiation of surveillance | Surveillance schedule | Recommended surveillance method |
|---|---|---|---|---|
| AGA (United States) | 2010 | 8–10 y after symptom onset PSC-IBD a : begin at diagnosis |
Every 1–20 y | |
| BSG (United Kingdom and Ireland) | 2010 | 8–10 y after symptom onset | Risk based | Chromoendoscopy with targeted biopsy Random biopsy (4 quadrant) every 10 cm if CE expertise unavailable |
| Low: 5 y—no inflammation, or left-sided colitis, or CD < 50% colon | ||||
| Intermediate: 3 y—mild inflammation, or pseudopolyps, or Fhx of >50 CRC | ||||
| High: 1 y—moderate inflammation, or stricture, OR PSC, or Fhx of CRC < 50 | ||||
| ECCO (European Consensus) | 2013 | 6–8 y after symptom onset | Risk based | Chromoendoscopy with targeted biopsies and mode of choice for trained endoscopists. WLE with random biopsy and targeted biopsy of any lesions is alternative |
| Risk factors: PSC, pancolitis, active inflammation, pseudopolyps, Fhx of CRC | ||||
| Low risk (1–2 Risk Factors): every 3–4 y | ||||
| High risk (3–4 Risk Factors): every 1–2 y |
Abbreviation: AGA, American Gastroenterological Association; BSG, British Society of Gastroenterology; CD, Crohn's disease; CE; chromoendoscopy; CRC, colorectal cancer; Fhx, family history; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis; WLE, white light endoscopy.
a
All societies recommend surveillance in all patients with IBD-related colitis, except isolated proctitis or CD involving less than 1 segment of the colon.